Navigation Links
NxStage Initiates 2013 'Call to Action' Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
Date:2/14/2013

LAWRENCE, Mass., Feb. 14, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM) is reinforcing its efforts with patients, care partners and renal professionals to increase awareness about the benefits of home hemodialysis (HHD) and advocate for reimbursement policy changes with the Centers for Medicare and Medicaid Services (CMS) specifically as it relates to reimbursement for HHD training.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

Today, the Company initiated its 2013 'Call to Action' campaign with the launch of  Hemodialysis at Home:  A Better Way For a Better Life.  This effort will support and showcase the strength of dialyzors, care partners, physicians, nurses, patient advocates, and other renal professionals who believe patients need to have better access to the improved survival, clinical benefits and quality of life reported by many patients receiving more frequent home hemodialysis.  The primary near-term goal of the project is to ensure that these supporters are heard by government officials and that current Medicare reimbursement for HHD training is fixed so that more patients have access to this therapy.

"Patients have a right to be fully informed of all of their treatment options and to choose whichever therapy is best for them," said Joe Turk , President, North America at NxStage Medical, Inc. "Hemodialysis at Home is aimed at stepping up our call to action campaign, increasing awareness, and showcasing the strength of support for HHD among dialyzors, care partners and the renal care community.  The site is geared to attracting those who seek action and providing opportunities to engage at whatever level possible to change policies that limit patient access to this life-changing therapy."

More frequent and at home treatments made possible with home hemodialysis can allow people with kidney disease the freedom and flexibility to reclaim their lives.  In fact, in a survey, more than 90% of nephrologists said they would choose a home dialysis therapy for themselves if informed they needed renal replacement therapy, with HHD being the preferred option.  But surprisingly, more than 90% of patients undergoing dialysis in the United States are doing three-times-weekly in-center therapy, a therapy very few physicians would accept for themselves.  

Supporters of Home Hemodialysis:  A Better Way For a Better Life believe patients need to be better educated about the treatment options that exist and that Medicare payment policies should not prevent them from doing the treatment that they – and their doctors – feel is best.

About Hemodialysis at Home:  A Better Way For a Better Life:  Hemodialysis at Home: A Better Way For A Better Life brings together dialyzors, care partners, physicians, nurses, patient advocates, and other renal professionals from across the country who believe patients need to have better access to and more awareness of the improved quality of life reported to be made possible by home dialysis technology.  Hemodialysis at Home: A Better Way For A Better Life is a project of NxStage.  For more information, please visit www.HemoAtHome.org.

About NxStage Medical Inc.
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
2. Robert Funari Joins NxStage Board of Directors
3. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
4. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
5. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
6. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
7. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
8. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
10. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
11. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):